Anxiety treatment has a frustrating problem: the medicines that help millions of people do not work equally well for everyone.
For some people with generalized anxiety disorder, treatment can mean months or years of finding the right combination of medication, psychotherapy and lifestyle support. Some medicines take time to work, while others can cause side effects that make long-term treatment difficult.
That is why an unusual experimental treatment has attracted so much attention.
In a phase 2b clinical trial published in JAMA in 2025, researchers studied MM120, a pharmaceutical formulation of lysergide, in adults with moderate-to-severe generalized anxiety disorder.
The results were encouraging—but they need to be understood in context.
What the study actually found
The randomized trial included 198 adults between 18 and 74 years old across 22 U.S. research sites. Participants received one of several doses of MM120 or placebo and were followed for 12 weeks.
The researchers found a statistically significant dose-response relationship at four weeks.
The 100-microgram and 200-microgram groups showed larger reductions in Hamilton Anxiety Rating Scale scores than the placebo group, while the lower doses did not show the same statistically significant effect.
The 100-microgram group was particularly interesting.
At week 12, 65% of participants in that group met the study’s definition of treatment response, compared with about 31% in the placebo group. About 48% met the study’s definition of remission, compared with about 21% receiving placebo.
Those numbers are certainly worth investigating.
But they are not the same thing as proving that one treatment permanently eliminates anxiety.
Why older adults may be especially interested
The trial included adults up to age 74, which makes the findings relevant to an older population—but it does not mean the treatment has been established specifically for older adults.
Anxiety can become complicated later in life.
Retirement, bereavement, chronic illness, changing independence, financial concerns, sleep problems and medication changes can all affect emotional well-being. Anxiety symptoms can also overlap with symptoms of other medical conditions.
That makes careful diagnosis especially important.
An older person experiencing persistent worry, sleep disruption, physical tension or difficulty concentrating should not assume that these symptoms are simply an unavoidable part of aging.
There may be effective treatments available now, and a healthcare professional can help determine what is actually causing the symptoms.
Why a single treatment is such a big idea
Most psychiatric medications are designed around repeated dosing.
A treatment that produces a meaningful effect after one supervised session would represent a very different model.
That is part of what makes the MM120 findings so interesting.
The trial found evidence of improvement beginning soon after treatment, with benefits continuing through the 12-week follow-up period. The researchers described the 100-microgram dose as the dose to carry forward into pivotal trials.
But there is an important distinction between lasting benefit and permanent change.
The study followed participants for 12 weeks. It cannot tell us whether benefits would continue for six months, one year or longer, or whether repeat treatment might eventually be necessary.
Those questions remain open.
The experience is not simply another pill
One reason this treatment cannot be viewed as an ordinary daily medication is the nature of its acute effects.
Perceptual changes were common in the trial. At the 100-microgram dose, more than 90% of participants experienced some form of visual perceptual change, while nausea and headache were also reported. More than 97% of participants across the MM120 dose groups had resolution of acute effects by 12 hours, according to the trial.
That means any future medical use would require carefully controlled clinical conditions.
This is particularly important for older adults, who may have multiple medications, cardiovascular conditions or other health considerations that could affect how an experimental psychiatric treatment is tolerated.
The fact that a treatment is being studied in a medical setting does not make unsupervised use safe.
The brain science is promising—but not settled
Lysergide acts primarily through serotonin-related signalling, particularly the 5-HT2A receptor system.
Scientists are investigating whether this activity can temporarily alter patterns of brain communication and potentially create a period in which psychological patterns become more flexible.
But popular descriptions sometimes go much further, claiming that psychedelic treatment simply “rewires” the brain or creates permanent new neural connections.
That is not established by this clinical trial.
Laboratory studies provide interesting clues about mechanisms such as neuroplasticity, but laboratory findings should not be treated as proof that a particular treatment permanently repairs a person’s brain.
The clinical question remains much simpler:
Do patients become meaningfully less anxious, and does that improvement last?
The phase 2b results suggest that this question deserves further study.
There is still a major hurdle: phase 3
A promising phase 2 trial is not the finish line.
Larger phase 3 trials need to determine whether the findings can be reproduced in broader populations and whether the benefits outweigh the risks.
Researchers will also need to understand which patients are most likely to benefit, how long the effect lasts, what happens with other psychiatric medications and how the treatment performs in people with common health conditions.
This matters enormously for older adults.
A treatment can look promising in a carefully selected research population and behave differently when used among people taking multiple medications or living with several chronic conditions.
What this means today
MM120 is not an established replacement for current anxiety treatment.
The 2025 trial provides encouraging phase 2 evidence, but regulatory approval and broader clinical adoption require additional evidence.
For someone living with persistent anxiety today, the practical message is not to wait for an experimental therapy.
Evidence-based options—including psychotherapy and established medications when appropriate—remain the foundation of treatment.
And anxiety that suddenly appears later in life deserves attention rather than dismissal. New symptoms can sometimes reflect medication effects, medical illness, sleep problems or other conditions that need evaluation.
A potentially important new chapter
The most interesting part of the MM120 story may not be the idea of a psychedelic medication itself.
It is the possibility that psychiatry could eventually develop treatments that work differently from conventional daily medications.
The phase 2b findings provide a reason for researchers to keep asking whether a carefully supervised, one-time intervention can produce sustained improvement in people with significant anxiety.
But science moves in stages.
For now, MM120 remains an investigational treatment, not a proven cure and not a medication people should attempt to use outside medical research.
The real test will come from larger and longer studies.
If those trials confirm meaningful, durable benefits with acceptable safety, the treatment could become an important new option for some people with generalized anxiety disorder.
For older adults who have spent years searching for better answers, that possibility is worth watching—but it is far too early to call it a finished revolution.
Photo by Jimmy Chan: https://www.pexels.com/photo/drops-on-a-colorful-wall-18317858/
